Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs
Novartis
Novartis
Pfizer
Pfizer
M.D. Anderson Cancer Center
Medical College of Wisconsin
Pfizer
Pfizer
Pfizer
Pfizer
Pfizer
Massachusetts General Hospital
Pfizer
Pfizer
Pfizer